The U.S. Food and Drug Administration (FDA) has issued an approval (status AP) for an Abbreviated New Drug Application (ANDA) numbered ANDA088010.
The application, submitted by VANGARD, covers an oral capsule dosage form of chlordiazepoxide hydrochloride 10 mg (product number 001). The product is marked as discontinued and is not a reference drug.
The original submission (type ORIG) was filed on March 28, 1983.
Regulatorische Updates22. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA088010 for Chlordiazepoxide Hydrochloride Capsule
FDA granted approval (status AP) for VANGARD's ANDA088010 covering a 10 mg oral capsule of chlordiazepoxide hydrochloride, listed as discontinued.
Zusammengestellt vom PharmaCountry-Team · Quelle: FDA.gov
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen